Literature DB >> 16232198

Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development.

Aki Shimada1, Junko Kano, Tadashi Ishiyama, Chigusa Okubo, Tatsuo Iijima, Yukio Morishita, Yuko Minami, Yukinori Inadome, Yujian Shu, Shintaro Sugita, Tomoyo Takeuchi, Masayuki Noguchi.   

Abstract

Atypical adenomatous hyperplasia (AAH) is classified as a precancerous lesion of lung adenocarcinoma. We established an immortalized AAH cell line (PL16T) and a human non-neoplastic bronchial epithelial cell line (PL16B) from the same patient by transfection with the gene for SV40 large T antigen. The expression profile of PL16T was compared with that of PL16B by the suppression subtractive hybridization method. From 704 selectively hybridized clones, we finally selected 25 fragments of mRNA that showed transcription levels more than three times higher in PL16T than in PL16B. Thirteen (52%) and eight (32%) of them encoded tumor-associated calcium signal transducer 2 (TACSTD2) and S100 calcium binding protein A2 (S100A2), respectively. The high transcription of TACSTD2 and S100A2 in PL16T was confirmed by in situ hybridization. In normal lung tissue, both TACSTD2 and S100A2 were expressed at very low levels, but seven and five of 14 AAH were positive for TACSTD2 and S100A2, respectively. The frequency of TACSTD2 positivity was increased in 16 of 22 bronchioloalveolar carcinomas (BAC) and adenocarcinoma with mixed subtype with BAC component (mixed BAC). Positivity for S100A2 occurred in four of 22 BAC and mixed BAC. The abnormal transcription of TACSTD2 and S100A2 are thought to be unique molecular markers of the preinvasive stage of lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16232198     DOI: 10.1111/j.1349-7006.2005.00100.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma.

Authors:  Hiromi Kobayashi; Yuko Minami; Yoichi Anami; Yuzuru Kondou; Tatsuo Iijima; Junko Kano; Yukio Morishita; Koji Tsuta; Shinichiro Hayashi; Masayuki Noguchi
Journal:  Virchows Arch       Date:  2010-05-16       Impact factor: 4.064

2.  Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma.

Authors:  Yunjung Kim; Aya Shiba-Ishii; Tomoki Nakagawa; Shun-Ichiro Iemura; Tohru Natsume; Noriyuki Nakano; Ryota Matsuoka; Shingo Sakashita; SangJoon Lee; Atsushi Kawaguchi; Yukio Sato; Masayuki Noguchi
Journal:  Oncogene       Date:  2018-06-07       Impact factor: 9.867

3.  Influenza A Virus Infection Triggers Pyroptosis and Apoptosis of Respiratory Epithelial Cells through the Type I Interferon Signaling Pathway in a Mutually Exclusive Manner.

Authors:  SangJoon Lee; Mikako Hirohama; Masayuki Noguchi; Kyosuke Nagata; Atsushi Kawaguchi
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

4.  DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma.

Authors:  Suhaida A Selamat; Janice S Galler; Amit D Joshi; M Nicky Fyfe; Mihaela Campan; Kimberly D Siegmund; Keith M Kerr; Ite A Laird-Offringa
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

5.  miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.

Authors:  Taiki Sato; Aya Shiba-Ishii; Yunjung Kim; Tomoko Dai; Ryan Edbert Husni; JeongMin Hong; Junko Kano; Shingo Sakashita; Tatsuo Iijima; Masayuki Noguchi
Journal:  Cancer Sci       Date:  2017-03       Impact factor: 6.716

6.  Ovarian carcinoma immunoreactive antigen domain 2 controls mitochondrial apoptosis in lung adenocarcinoma.

Authors:  Jeongmin Hong; Aya Shiba-Ishii; Yunjung Kim; Masayuki Noguchi; Noriaki Sakamoto
Journal:  Cancer Sci       Date:  2021-10-18       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.